...
首页> 外文期刊>The Journal of molecular diagnostics: JMD >Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing
【24h】

Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing

机译:聚集定期间隙短的回文重复(CRISPR)/ CRISPR相关的内切核酸CAS9介导的同源无关集成,用于产生临床分子遗传检测的质量控制材料

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Genome-edited human cell tines are important resources for producing quality control materials for clinical molecular genetic testing. Generating cell lines with defined mutations through homology-directed repair based methods are inefficient and can Lead to unwanted insertions and deletions in the target loci. Nonhomologous end joining in the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated endonuclease Cas9 (Cas9) system was harnessed to generate genome-engineered cell lines harboring target mutations. Donor plasmids containing target sites for the single guide RNA (sgRNA) and homologous DNA fragments harboring important cancer gene mutations were cotransfected with the Cas9/sg RNA vector into wild-type human cells. The introduced mutations were validated in-house and in 44 laboratories using various techniques, including next-generation sequencing. Exogenous sequences containing the target mutations were efficiently integrated into the ALK receptor tyrosine kinase (ALK) locus in HEK293T and A549 cells. Successful introduction of artificial mutations was confirmed via both Sanger sequencing and the amplification refractory mutation system. Results of external pilot testing revealed that the DNA samples derived from genome-edited cell lines were widely applicable across multiple platforms and laboratories. This study demonstrates that CRISPR/Cas9-induced nonhomologous end joining is a valuable and novel method for generating artificial mutants for use in quality control applications in clinical molecular genetics.
机译:基因组编辑的人细胞曲线是生产临床分子遗传检测质量控制材料的重要资源。通过同源定向修复的方法产生具有定义突变的细胞系效率低,并且可以导致目标基因座中的不需要的插入和删除。利用在聚类中加入在聚类中的非宏观源结束的短语重复(CRISPR)/ CRISPR相关的内切核酸酶CAS9(CAS9)系统,以产生含有靶突变的基因组工程细胞系。将含有单引导RNA(SGRNA)的靶位点和含有重要癌症基因突变的同源DNA片段的供体质粒被Cas9 / SG RNA载体分配到野生型人体细胞中。引入的突变在房屋内验证,并使用各种技术,包括下一代测序的44个实验室。含有靶突变的外源序列在HEK293T和A549细胞中有效地集成到ALK受体酪氨酸激酶(ALK)基因座中。通过Sanger测序和扩增耐火突变系统确认了人为突变的成功引入。外部试验检测结果显示,衍生自基因组编辑细胞系的DNA样品广泛适用于多个平台和实验室。该研究表明CRISPR / CAS9诱导的非汉语终端连接是用于在临床分子遗传学中用于质量控制应用的人工突变体的有价值和新的方法。

著录项

  • 来源
  • 作者单位

    Beijing Hosp Natl Ctr Gerontol Natl Ctr Clin Labs Beijing Peoples R China;

    Beijing Hosp Natl Ctr Gerontol Natl Ctr Clin Labs Beijing Peoples R China;

    Beijing Hosp Natl Ctr Gerontol Natl Ctr Clin Labs Beijing Peoples R China;

    Beijing Hosp Natl Ctr Gerontol Natl Ctr Clin Labs Beijing Peoples R China;

    Beijing Hosp Natl Ctr Gerontol Natl Ctr Clin Labs Beijing Peoples R China;

    Beijing Hosp Natl Ctr Gerontol Natl Ctr Clin Labs Beijing Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 临床医学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号